Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial
#4PRI RANKED
Most Cited Paper
in Retinal Diseases and Treatments
18 Months Post-Publication
Class of 2026
“Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/retinal-diseases-and-treatments/2026/
Topics
Aflibercept · Neovascular age-related macular degeneration · PULSAR trial · Noninferiority trial design · Extended dosing interval · Anti-VEGF therapy · Best-corrected visual acuity (BCVA) · Aflibercept · Extended dosing interval · Intraretinal fluid resolution
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Retinal Diseases and Treatments Papers, Class of 2026. https://pri.pepkio.com/top-papers/retinal-diseases-and-treatments/2026. Accessed 2026-07-13. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459